Genetic predisposition and nongenetic risk factors of thiazolidinedione- related edema in patients with type 2 diabetes

Pharmacogenetics and Genomics

Volumn 21, Issue 12, 2011, Pages 829-836

  Chang, Tien Jyun ^a   Liu, Pi Hua ^g   Liang, Yi Chi ^c   Chang, Yi Cheng ^a,e   Jiang, Yi Der ^a   Li, Hung Yuan ^a   Lo, Min Tzu ^b   Chen, Harn Shen ^f   Chuang, Lee Ming ^a,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Institute of Sports Medicine   (China)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

edema; pharmacogenetics; thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE;

ALLELE; ARTICLE; CONFIDENCE INTERVAL; DIABETIC PATIENT; EDEMA; FEMALE; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

EID: 81055156102     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834bfff1     Document Type: Article

References (32)

1. Yki-Jä rvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
2. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003; 46:288-290. (Pubitemid 36343894)
3. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89:6068-6076. (Pubitemid 39628416)
4. Tan M, Johns D, Gonzá lez Gá lvez G, Antúnez O, Fabián G, Flores-Lozano F, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004; 26:680-693. (Pubitemid 38736958)
5. Raskin P, McGill J, Saad MF, Cappleman JM, Kaye W, Khutoryansky N, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med 2004; 21:329-335. (Pubitemid 38519667)
6. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24:1226-1232. (Pubitemid 33716403)
7. Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, et al. Variation at the NFATC2 locus increases the risk of thiazolinedinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care 2010; 33: 2250-2253.
8. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004; 308:426-433. (Pubitemid 38134200)
9. Knepper MA,Wade JB, Terris J, Ecelbarger CA, Marples D, Mndon B, et al. Renal aquaporins. Kidney Int 1996; 49:1712-1717. (Pubitemid 26188068)
10. Knepper MA. Proteomics and the kidney. J Am Soc Nephrol 2002; 13:1398-1408. (Pubitemid 34441423)
11. Guan Y, Zhang Y, Davis LM, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273:F1013-F1022.
12. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005; 102:9406-9411. (Pubitemid 40923576)
13. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaCmediated renal salt absorption. Nat Med 2005; 11:861-866. (Pubitemid 41161118)
14. Hansen L, Ekstrøm CT, Palacios RT, Anant M,Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-g/a agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006; 91:3446-3450. (Pubitemid 44402117)
15. Rennings AJ, Smits P, Stewart MW, Tack CJ. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage. Diabetologia 2010; 53:1856-1866.
16. Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, et al. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. Pharmacogenet Genomics 2008; 18:903-910.
17. Spraggs C, McCarthy A, McCarthy L, Hong G, Hughes A, Lin X, et al. Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenet Genomics 2007; 17:1065-1076. (Pubitemid 351339491)
18. Lin X, Song K, Lim N, Yuan X, Johnson T, Abderrahmani A, et al. Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score-the CoLaus Study. Diabetologia 2009; 52:600-608.
19. Barrett JC, Fry B, Maller J, Daly MJ. haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
20. Tobler AR, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM, et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J Biomol Tech 2005; 16:398-406.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: Wiley; 2000.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44:837-845.
23. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172 and 207-212. (Pubitemid 351193639)
24. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974; 99:325-332.
25. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: the framingham study risk score functions. Stat Med 2004; 23:1631-1660. (Pubitemid 38660414)
26. Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton: Chapman & Hall/CRC; 1994.
27. Lei HH, Chen MH, Yang WS, Chiu MC, Chen MC, Tai TY, et al. Peroxisome proliferator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000; 49:1267-1270.
28. Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL, et al. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta 2009; 400:48-55.
29. Tiwari S, Blasi ER, Heyen JR, McHarg AD, Ecelbarger CM. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats. Pharmacol Res 2008; 57:383-392.
30. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40:592-599. (Pubitemid 351601207)
31. Adachi M, Asakura Y, Sato Y, Tajima T, Nakajima T, Yamamoto T, et al. Novel SLC12A1 (NKCC2) mutations in 2 families with Bartter syndrome type 1. Endocr J 2007; 54:1003-1007. (Pubitemid 351346786)
32. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, et al. Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther 2007; 82:300-309. (Pubitemid 47260543)